VERAXA Biotech Reports Proof-of-Concept Data for BiTAC-ADC Platform, Seeks Partnerships at BIO 2026

VERAXA Biotech AG (NASDAQ: VRXA), a company focused on designing next-generation cancer therapies, has announced new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology aimed at improving the selectivity of antibody-drug conjugates (ADCs) in cancer treatment. The results, released ahead of the company’s participation in the BIO International Convention 2026 in San Diego (https://nnw.fm/APy2D), demonstrate the platform’s ability to distinguish between breast cancer cells and healthy cells in laboratory studies, as well as dose-dependent destruction of three-dimensional tumor cell spheroids.

The BiTAC-ADC platform is part of VERAXA’s proprietary BiTAC approach, which is designed to activate therapeutic effects only within targeted tumor cells, thereby sparing healthy tissue. This selectivity could address a key limitation of conventional ADCs, which often cause off-target toxicity. The company also highlighted its BiTAC-TCE (T-cell engager) platform as another candidate for potential strategic collaborations.

VERAXA maintains a diversified oncology pipeline that includes ADCs, T-cell engagers, and other antibody-based formats. The company recently began trading on the NASDAQ Capital Market under the ticker VRXA after completing a business combination with Voyager Acquisition Corp. This move provides VERAXA with access to public capital markets to advance its pipeline.

The announcement is significant for the biotechnology sector, as it underscores the ongoing efforts to develop more precise cancer therapies. The BiTAC-ADC platform’s early data suggest it could offer a safer alternative to existing ADCs, potentially reducing side effects for patients. However, the platform remains in early development, and further studies will be needed to confirm its efficacy and safety in clinical settings.

For investors, the news provides insight into VERAXA’s technological progress and its strategy to partner with larger pharmaceutical companies. The company’s presence at the BIO International Convention, a major industry event, indicates its active pursuit of collaborations to advance its platforms. The latest news and updates relating to VRXA are available in the company’s newsroom at https://nnw.fm/VRXA.

As the cancer therapy landscape evolves, platforms like BiTAC-ADC could play a crucial role in enabling more targeted treatments. The in vitro data provide a foundation for future development, but the path to clinical use involves rigorous testing and regulatory approvals. VERAXA’s ability to secure partnerships and funding will be critical to moving its candidates forward.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is VERAXA Biotech Reports Proof-of-Concept Data for BiTAC-ADC Platform, Seeks Partnerships at BIO 2026.

The post VERAXA Biotech Reports Proof-of-Concept Data for BiTAC-ADC Platform, Seeks Partnerships at BIO 2026 appeared first on citybuzz.